Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder associated with elevated cardiometabolic risk. The authors set out to investigate the poorly understood role of the renin-angiotensin system (RAS)–iron metabolism axis in mediating PCOS comorbidity with cardiometabolic conditions. The study also evaluated the therapeutic potential of the natural compound gentiopicroside.
The investigation applied an integrated multi-omics workflow to identify shared molecular pathways and candidate therapeutic targets across PCOS and related cardiometabolic disorders (hypertension, nonalcoholic fatty liver disease [NAFLD], and type 2 diabetes mellitus [T2DM]). The analytic approaches reported in the abstract included:
The abstract lists these components as the core methods used to link molecular observations with functional and therapeutic assessments.
Across PCOS transcriptomic datasets, SLC11A2 was reported as consistently dysregulated. Analyses associated SLC11A2 with pathways central to iron metabolism, inflammatory responses, and oxidative stress. Single-cell analyses further characterized SLC11A2-associated molecular patterns within disease-relevant cell types, indicating the gene’s involvement at cellular resolution in tissues implicated in PCOS and cardiometabolic comorbidities.
Genetic investigations validated RAS-related regulation affecting susceptibility to hypertension. The authors also reported evidence of a shared genetic architecture between PCOS and cardiometabolic traits, supporting the hypothesis that overlapping genetic determinants—potentially mediated through RAS pathways—influence both ovarian dysfunction and cardiometabolic risk phenotypes.
Network analyses mapped SLC11A2-associated molecular interactions and pathways relevant to inflammation and oxidative stress. Machine learning approaches were used to identify molecular signatures capable of classifying disease states across the studied conditions. Molecular docking was incorporated into the pipeline to explore potential interactions of candidate therapeutic molecules with target proteins identified from the multi-omics integration.
Functional assays performed in vitro evaluated therapeutic candidates emerging from the integrated analyses. The abstract reports that gentiopicroside alleviated inflammatory and oxidative stress phenotypes in these assays. Specifically, treatment with gentiopicroside was associated with reduced IL-6 expression and decreased accumulation of reactive oxygen species (ROS) in the experimental systems described in the study summary.
The combined multi-omics and experimental findings led the authors to define an RAS–SLC11A2 molecular framework that links dysregulated iron metabolism to PCOS-related cardiometabolic risk. This framework is presented as elucidating mechanisms that connect ovarian dysfunction with systemic processes including inflammation, oxidative stress, and hypertension.
Based on the reported results, the study supports the potential of targeting the RAS–iron metabolism axis in PCOS to address cardiometabolic risk. The authors propose gentiopicroside as a promising therapeutic candidate because it demonstrated anti-inflammatory and antioxidant effects in the reported in vitro assays, such as lowering IL-6 expression and ROS accumulation.
The authors list the following keywords: Iron metabolism; Polycystic ovary syndrome; SLC11A2; gentiopicroside; hypertension; renin-angiotensin system. MeSH terms and indexed subjects in the record include cardiometabolic risk factors, iron metabolism, oxidative stress, multiomics, and genetic and drug therapy aspects of PCOS.
Note on unreported details
The abstract provides high-level descriptions of methods and findings but does not report sample sizes, specific datasets or cohorts used, statistical effect sizes, cellular subtypes by name, or detailed experimental conditions for the in vitro assays. Those details were not reported in the provided source text and therefore are not included here.